Frontlight ResearchEarly access
TerminatedNo phase
Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
Key facts
- Who runs it
- M.D. Anderson Cancer Center
- Where
- Houston, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 27 people enrolled
- Started
- 15 Aug 2022
- Ended
- 21 Aug 2024
- Type of study
- Observational
- Treatments tested
- Behavioral Assessment
- Electronic Health Record Review
- Record updated
- 26 August 2024
- Why it stopped
- IRB Study Closure
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Patients with pathologically confirmed breast cancer with any receptor status, who will receive neoadjuvant chemotherapy. Patients with denovo oligo-metastatic disease, where the intent of therapy is curative with incorporation of local therapy (surgery/radiation to the breast and/or metastatic sites) are also eligible
- Age >= 18 years
- Ability to understand and the willingness to sign a written informed consent
- Willingness to wear sensors to track physical activity, global positioning system (GPS) location, and provide symptom ratings each night during the screening period of their clinical trial and 180 days after starting treatments
- Able to read English, Spanish, or Mandarin to complete patient reported outcomes
- Able to ambulate without an assistive device
Who cannot take part
- Known movement disorder such as Parkinson's disease, choreo-athetoid movement disorders, essential tremor if that movement disorder is of sufficient severity to require drug therapy
- Missing lower limbs
Where in United States
- M D Anderson Cancer CenterHouston, United States
About the trial
What the trial wants to find out
This study assesses the performance status in stage I-III triple negative breast cancer patients who are receiving neoadjuvant chemotherapy. Information collected in this study may help doctors learn if movement and fitness trackers can be used to predict side effects in cancer patients receiving chemotherapy.
The group in the trial
- Observational (movement assessment, medical data collection)
Patients complete movement assessment 5-15 days prior to the initiation of neoadjuvant chemotherapy and at day 1 of neoadjuvant chemotherapy. Patients' SAE data is collected. Patients are observed during their neoadjuvant chemotherapy for up to 6 months.
Treatment: Behavioral Assessment and Electronic Health Record Review
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 26 August 2024